Rapid switch from intravenous epoprostenol to intravenous Remodulin(Rm) (Treprostinil sodium) in patients with stable pulmonary arterial hypertension: safety, efficacy and treatment satisfaction.

Trial Profile

Rapid switch from intravenous epoprostenol to intravenous Remodulin(Rm) (Treprostinil sodium) in patients with stable pulmonary arterial hypertension: safety, efficacy and treatment satisfaction.

Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Jan 2013

At a glance

  • Drugs Treprostinil (Primary)
  • Indications Pulmonary hypertension
  • Focus Therapeutic Use
  • Sponsors United Therapeutics Corporation
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 24 Mar 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 24 Mar 2009 Actual patient number (10) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top